Form Health Unveils New Program to Prevent the Transition from Overweight to Obesity
Form Health launched a new program for people who are overweight that includes meetings with a registered dietitian and a personalized care plan.
Metabolic Meds Startup Verdiva Launches With $411M and a Weekly Oral GLP-1 Drug
Verdiva Bio’s once-a-week oral GLP-1 drug is ready for Phase 2 testing. The drug, made with a proprietary technology that enables oral dosing, was licensed from Sciwind Biosciences.
Solving Healthcare’s Provider Data Problem Starts with Interoperability
Break down the silos. Take control of your provider data.
Biopharma in 2025: Outlook for Obesity Meds, Drug Prices, Regulation & More
Metabolic medicines dominated life sciences headlines in 2024, a trend expected to continue into the new year. Other things to look for include more widespread adoption of artificial intelligence technologies and the IPO market’s return to normal levels.
Study: Why Quick Fixes Don’t Work in Workplace Wellness
By grounding wellness programs in behavior-change science, employers can empower their people to build healthier, more sustainable habits.
Novo Nordisk Adds Obesity and Diabetes to AI Drug Research Pact With Flagship’s Valo Health
Novo Nordisk and Valo Health have collaborated on the development of cardiovascular disease drugs since 2023. Expanding the alliance to cardiometabolic diseases nearly doubles the number of programs covered under the agreement.
The Chase for Novel Oral GLP-1 Obesity Meds Adds a New Contender
Corxel Pharmaceuticals has acquired an oral small molecule GLP-1 agonist with potential applications in obesity and diabetes. The Phase 2-ready pill could compete with oral metabolic meds in development by companies such as Roche, AstraZeneca, and Structure Therapeutics.
presented by
The Top 5 Home Care Franchise Opportunities in the U.S.
The home care industry is booming. As Baby Boomers age and more families seek in-home solutions for loved ones, demand for home care services is at an all-time high.
Safety Signal in Phase 2 Deals a Setback to BioAge Labs’ Muscle-Preserving Obesity Drug
BioAge Labs said the potential safety problem was observed in some who received experimental drug azelaprag, which is being tested as a monotherapy and in combination with Eli Lilly obesity medication Zepbound. No safety signals were observed in those who received Zepbound alone.
Eli Lilly’s Zepbound Leads to Greater Weight Loss vs. Novo Nordisk Drug in Head-to-Head Test
Eli Lilly obesity drug Zepbound led to 47% greater relative weight loss compared to Wegovy in a head-to-head clinical trial. The results could help Lilly differentiate its product from Novo Nordisk’s in the increasingly competitive market of obesity medications.
Health Leaders Applaud Biden’s Proposal to Expand Medicare/Medicaid Coverage for Anti-Obesity Medications
Several healthcare leaders are supporting the Biden-Harris administration’s proposed rule to expand Medicare and Medicaid coverage of GLP-1 medications for obesity treatment.
Weight Loss With Amgen Drug in Line With Eli Lilly Med, But Dosing Could Be Differentiator
Amgen’s experimental obesity drug, MariTide, led to an average 20% reduction in weight in a Phase 2 clinical trial. While investors hoped for greater weight loss, some analysts say less burdensome monthly dosing of MariTide could make it competitive against weekly injectable weight drugs Zepbound and Wegovy.
presented by
Why Workflow Chaos Is Undermining Care – and What Providers Can Do About It.
Healthcare is drowning in chaos—from scattered data to burnout-inducing tasks. Discover how smarter workflows and real-time insights can rescue care teams and transform patient outcomes.
Why Digital Twin Technology Could Help Maximize GLP-1 Efficacy
Digital twin technology can serve as an effective complement to some of the exciting advancements occurring in the metabolic health space, such as new generations of continuous glucose monitors and a slew of GLP-1s, according to Lisa Shah, chief medical officer at Twin Health.
Viking Therapeutics’ Early Clinical Data Continue to Build Case for Its Oral Obesity Drug
Higher doses of a Viking Therapeutics pill that targets two receptors led to greater weight loss without worsening safety or tolerability, according to Phase 1 results presented during the ObesityWeek conference. Meanwhile, an injectable version of this Viking drug is on track to Phase 3 testing.
Exercise Benefit in a Pill: BioAge Labs Goes Public, Raising More Than $200M for Clinical Trials
BioAge Labs’ lead drug candidate, azelaprag, is in Phase 2 testing in combination with Eli Lilly’s weight management medication Zepbound. The biotech’s oral drug activates a receptor it says can mimic certain biological effects of exercise.
Tackling Global Obesity: The New, Holistic Frontier for Clinical Trials
To conduct meaningful research, we must be sure to view these studies through patients’ eyes. The patient perspective — in all its diversity — must be embedded into clinical trials from the very start.
Terns Pharma Oral GLP-1 Drug Leads to Greater Than 5% Weight Loss in Small Study
The weight loss results for the Terns Pharmaceuticals drug TERN-601 come from a four-week Phase 1 clinical trial. Terns is one of several companies developing oral GLP-1 obesity medications that could become alternatives to currently available injectable products from this drug class.